The neurochemistry of Alzheimer's disease

Acta Neurologica Belgica

Volumn 97, Issue 2, 1997, Pages 67-84

  Engelborghs, S ^b   De Deyn, P P ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b NONE

Author keywords

Alzheimer's disease; Cytokines; Dementia; Neuro chemistry; Neuropeptides; Neurotransmitters

Indexed keywords

ADRENALIN; AMINO ACID; CATECHOLAMINE; CYTOKINE; DOPAMINE; NEUROPEPTIDE Y; NEUROTRANSMITTER; NORADRENALIN; SOMATOSTATIN; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; AMINO ACID BRAIN LEVEL; CEREBROSPINAL FLUID; CHOLINERGIC SYSTEM; DORSAL RAPHE NUCLEUS; HUMAN; LOCUS CERULEUS; NEUROCHEMISTRY; NORADRENERGIC SYSTEM; OLIVARY NUCLEUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW;

EID: 0030841833     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (226)

1. ADOLFSSON R., GOTIFRIES C. G., ROOS B. E., WINBLAD B. Changes in the brain catecholamines in patients with dementia of the Alzheimer type. Br. J. Psychiatry, 1979, 135 : 216-223.
2. 2+ mobilization by cloned human somatostatin receptor subtypes 1-5, in transfected COS-7 cells. FEBS Lett., 1994, 348 : 192-196.
3. ALHAINEN K., SIRVIO J., HELKALA E. L., REINIKAINEN K., RIEKKINFN P. Somatostatin and cognitive functions in Alzheimer's disease - the relationship of cerebrospinal fluid somatostatin increase with clinical response to tetrahydroaminoacridine. Neurosci. Lett., 1991, 130 : 46-48.
4. 3H)GBR-12935 in Alzheimer's disease. Eur. Neurol., 1990, 31 : 181-185.
5. ALLARD P. O., RINNE J., MARCUSSON J. O. Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type. Brain Res., 1994, 637 : 262-266.
6. ARAGA S., KAGIMOTO H., FUNAMOTO K., TAKAHASHI K. Reduced natural killer cell activity in patients with dementia of the Alzheimer type. Acta Neurol. Scand., 1991, 84 : 259-263.
7. ARAI H., KOSAKA K., IIZUKA R. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J. Neurochem., 1984, 43 : 388-393.
8. ARAI H., MOROJI T., KOSAKA K. Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer's disease. Neurosci. Lett., 1984, 52 : 73-78.
9. ARAUJO D. M., LAPCHAK P. A., ROBITAILLE Y., GAUTHIER S., QUIRION R. Differential alterations of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J. Neurochem., 1988, 50 : 1914-1923.
10. ARAUJO D. M., COTMAN C. W. Betα-amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res., 1992, 569 : 141-145.
11. ARMSTRONG D. M., LEROY S., SHIELDS D., TERRY R. D. Somatostatin-Like Immunoreactivity Within Neuritic Plaques. Brain Res., 1985, 338 : 71-79.
12. ARMSTRONG D. M., IKONOMOVIC M. D., SHEFFIELD R., WENTHOLD R. J. AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of the non-demented elderly and patients with Alzheimer's disease. Brain Res., 1994, 639 : 207-216.
13. ASHALL F., GOATE A. M. Role of the β-amyloid precursor protein in Alzheimer's disease. TIBS, 1994, 19 : 42-46.
14. ATACK J. R., BEAL M. F., MAY C., KAYE J. A., MAZUREK M. F. et al. Cerebrospinal fluid somatostatin and neuropeptide Y. Concentrations in aging and in dementia of the Alzheimer type with and without extrapyramidal signs. Arch. Neurol, 1988, 45 : 269-274.
15. BALAZS L., LEON M. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem. Res., 1994, 19: 1131-1137.
16. BARGER S. W., VAN ELDIK L. J. S100β stimulates calcium fluxes in glial and neuronal cells. J. Biol. Chem., 1992, 267 : 9689-9694.
17. BARNES N. M., COSTALL B., NAYLOR R. J., WILLIAMS T. J., WISCHIK C. M. Normal densities of 5-HT3 receptor recognition sites in Alzheimer's disease. Neuroreport, 1990, 1 : 253-254.
18. BAUER J., STRAUSS S., SCHREIIER-GASSER U., GANTER U., SCHLEGFL P. et al. Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett., 1991, 285 : 111-114.
19. BEAL M. F., MAZUREK M. F., TRAN V. T., CHATTA G., BIRD E. D. et al. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science, 1985, 229 : 289-291.
20. BEAL M. F., MAZUREK M. F., SVENDSEN C. N., BIRD E. D., MARTIN J. B. Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex of Alzheimer's disease. Ann. Neurol., 1986a, 20 : 489-495.
21. BEAL M. F., BENOIT R., MAZUREK M. F., BIRD E. D., MARTIN J. B. Somatostatin-28(I-12)-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Brain Res., 1986b, 368 : 380-383.
22. BEAL M. F., GROWDON J. H., MAZUREK M. F., MARTIN J. B. CSF somatostatin-like immunoreactivity in dementia. Neurology, 1986c, 36 : 274-277.
23. BERGSTROM L., GARLIND A., NILSSON L., ALAFUZOFF I., FOWLER C. J. et al. Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain. J. Neurol. Sci., 1991, 105 : 225-233.
24. BIERER L. M., HAROUTUNIAN V., GABRIEL S., KNOTT P. J., CARLIN L. S. et al. Neurochemical correlates of dementia severity in Alzheimer's disease : relative importance of the cholinergic deficits. J. Neurochem., 1995, 64 : 749-760.
25. BIRD T. D., STRANAHAN S., SUMI S. M., RASKIND M. Alzheimer's disease : choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann. Neurol., 1983, 14 : 284-293.
26. BISSETTE G., MEYERS B. Somatostatin in Alzheimer's disease and depression. Life Sci., 1992, 51 : 1389-1410.
27. BLENNOW K., WALLIN A., GOTTFRIES C. G., LEKMAN A., KARLSSON I. et al. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol. Aging, 1992, 13 : 107-113.
28. BLISS T. V., COLLINGRIDGE G. L. A synaptic model of memory : long-term potentiation in the hippocampus. Nature, 1993, 361 : 31-39.
29. BONDAREFF W., MOUNTJOY C. Q., ROTH M. Selective loss of neurons of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet, 1981, (i) : 783-784.
30. BONDAREFF W., MOUNTJOY C. Q., ROTH M., ROSSOR M. N., IVERSEN L. L. et al. Age and histopathologic heterogeneity in Alzheimer's disease. Evidence for subtypes. Arch. Gen. Psychiatry, 1987, 44 : 412-417.
31. BONDY S. C. The relation of oxidative stress and hyperexcitation to neurological disease. Proc. Soc. Exp. Biol Med., 1995, 208 : 337-345.
32. BOWEN D. M., BENTON J. S., SPILLANE J. A., SMITH C. C., ALEN S. J. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J. Neurol. Sci., 1982, 57 : 191-202.
33. BRACCO F., SCARPA M., RIGO A., BATTISTIN L. Determination of Superoxide dismutase activity by the polarographic method of catalytic currents in the cerebrospinal fluid of aging brain and neurologic degenerative diseases. Proc. Soc. Exp. Biol. Med., 1991, 196 : 36-41.
34. BRANN M. R., ELLIS J., JORGENSEN H., HILL-EUBANKS D., JONES S. V. P. Muscarinic acetylcholine receptor subtypes : localization and structure / function. In : Progress in Brain Research., vol. 98 : Cholinergic Function and Dysfunction. CUELLO A. C. (ed.), Amsterdam, Elsevier, 1993 : 121-127.
35. BROWNSTEIN M., ARIMURA A., SATO H., SCHALLY A. V., KIZER J. S. The regional distribution of somatostatin in the rat brain. Endocrinol., 1975, 96 : 1456-1461.
36. CACABELOS R., BARQUERO M., GARCIA P., ALVAREZ X. A., VARELA DE SEIJAS E. Cerebrospinal fluid interleukin-1 beta in Alzheimer's disease and neurological disorders. Methods Find Exp. Clin. Pharmacol., 1991a, 13 : 455-458.
37. CACABELOS R., FRANCO-MASIDE A., ALVAREZ X. A. Interleukin-1 in Alzheimer's disease and multi-infarct dementia : neuropsychological correlations. Methods Find Exp. Clin. Pharmacol., 1991b, 13 : 703-708.
38. CACABELOS R., ALVAREZ X. A., FRANCO-MASIDE A., FERNANDEZ-NOVOA L. and CAAMANO J. Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia. Methods Find Exp. Clin. Pharmacol., 1994, 16 : 29-35.
39. CEBALLOS I., JAVOY-AGID F., HIRSCH E., DUMAS S., KAMOUN P. P. et al. Localization of copper-zinc superoxide dismutase mRNA in human hippocampus by in situ hybridization. Neurosci. Lett., 1989, 105 : 41-46.
40. CEBALLOS I., JAVOY-AGID F., DELACOURTE A., DEFOSSEZ A., LAFON M. et al. Neuronal localization of copper-zinc superoxide dismutase protein and mRNA within the human hippocampus from control and Alzheimer's disease brains. Free Rad. Res. Comm., 1991, 12-13 : 571-580.
41. CHAN-PALAY V. Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold / silver intensification on vibratome sections : coexistence with neuropeptide Y neurons, and effects in Alzheimer-type dementia. J. Compar. Neurol., 1987, 260 : 201-223.
42. CHEN L., RICHARDSON J. S., CALDWELL J. E., ANG L. C. Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer's disease and from nondemented controls. Intern. J. Neuroscience, 1994, 75 : 83-90.
43. CHENG A. V., FERRIER I. N., MORRIS C. M., JABEEN S., SAHGAL A. et al. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's disease and Parkinson's disease. J. Neurol. Sci., 1991, 106 : 50-55.
44. A receptors in Alzheimer's disease : a quantitative autoradiographic study. Neurology, 1987a, 37 : 1454-1459.
45. A receptor changes in Alzheimer's disease. Neurosci. Lett., 1987b, 82 : 246-252.
46. COLLERTON D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience, 1986, 19 : 1-28.
47. CORTÉS R., PROBST A., PALACIOS J. M. Decreased densities of dopamine D1 receptors in the putamen and hippoacampus in senile dementia of the Alzheimer type. Brain Res., 1988, 475 : 164-167.
48. COYLE J. T., PRICE D. L., DELONG M. R. Alzheimer's disease : disorder of cortical cholinergic innervation. Science, 1983, 219 : 1184-1190.
49. CRAMER H., SCHAUDT D., RISSLER K., STRUBEL D., WARTER J. M. et al. Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type., multi-infarct syndrome and communicating hydrocephalus. J. Neurol., 1985, 232 : 346-351.
50. CROSS A. J., CROW T. J., JOHNSON J. A., JOSEPH M. H., PERRY E. K. et al. Monoamine metabolism in senile dementia of Alzheimer type. J. Neurol. Sci., 1983, 60: 383-392.
51. CROSS A. J., CROW T. J., FERRIER L. N., JOHNSON J. A., MARKAKIS D. Striatal dopamine receptors in Alzheimer-type dementia. Neurosci. Lett., 1984a, 64 : 109-117.
52. CROSS A. J., CROW T. J., FERRIER I. N., JOHNSON J. A., BLOOM S. R. et al. Serotonin receptor changes in dementia of the Alzheimer type. J. Neurochem., 1984b, 43 : 1574-1581.
53. CROSS A. J., CROW T. J., JOHNSON J. A., PERRY E. K., PERRY R. H. et al. Studies on neurotransmitter receptor systems in the neocortex and hippocampus in senile dementia of the Alzheimer type. J. Neurol. Sci., 1984c, 64 : 109-117.
54. CROSS A. J., CROW T. J., FERRIER I. N., JOHNSON J. A. The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia. Neurobiol. Aging, 1986, 7 : 3-7.
55. CURCIO C. A., KEMPER T. Nucleus raphe dorsalis in dementia of the Alzheimer type : neurofibrillary changes and neuronal packing density. J. Neuropathol. Exp. Neurol., 1984, 143 : 359-368.
56. DAVIES P., MALONEY A. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, 1976, ii : 1403.
57. DAVIES P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res., 1979, 171 : 319-327.
58. DAVIES P., KATZMAN R., TERRY R. D. Reduced somatostatin-like-immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer's senile dementia. Nature, 1980, 288 : 279-280.
59. DAVIES C. A., MOROLL D. R., PRINJA D., MANN D. M. A., GIBBS A. A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease. J. Neurol. Sci., 1990, 96 : 59-73.
60. DAVIS K. L., HSIFH J. Y., LEVY M. I., HORVATH T. B., DAVIS B. M. et al. Cerebrospinal fluid acetylcholine, choline and senile dementia of the Alzheimer type. Psychopharmacol. Bull., 1982, 18 : 193-195.
61. DE DEYN P. P., HIRAMATSU M., BORGGREVE F., GOEMAN J., D'HOOGE R. et al. Free radicals and Superoxide dismutase in dementia. In : Free Radicals in Brain Physiology and Disorders. PACKER L., HIRAMATSU M., YOSHIKAWA T. (eds.), San Diego, Academic Press, 1996, 293-312.
62. DE DEYN P. P., HIRAMATSU M., BORGGREVE F., GOEMAN J., D'HOOGF R. et al. Superoxide dismutase activity in cerebrospinal fluid of patients with dementia and some other neurological disorders. Alzheimer Dis. Assoc. Disord., in press.
63. DEGRELL I., HELLSING K., NAGY E., NIKLASSON F. Amino acid concentrations in cerebrospinal fluid in presenile and senile dementia of Alzheimer type and multi-infarct dementia. Arch. Gerontol. Geriatr., 1989, 9 : 123-135.
64. 1-dopamine receptor abnormality in frontal cortex points to a functional alteration of cortical cell membranes in Alzheimer's disease. Arch. Neurol., 1990, 47 : 761-763.
65. DE KEYSER J. Loss of high-affinity agonist receptor binding in Alzheimer's disease (letter). Ann. Neurol., 1992, 31 : 231-232.
66. DELACOURTE A., DEFOSSEZ A., CEBALLOS I., NICOLE A., SINET P. M. Preferential localisation of copper zinc superoxide dismutase in the vulnerable cortical neurons in Alzheimer's disease. Neurosci. Lett., 1988, 92 : 247-253.
67. DEL BAL E. A., SLATER P. Binding to the glycine site of the NMDA receptor complex in brains of patients with Alzheimer's disease. Neurosci. Lett., 1991, 131 : 75-78.
68. DE LUSTIG E. S., SERRA J. A., KOHAN S., CANZIANI G. A., FAMULARI A. L. et al. Copper-zinc superoxide dismutase activity in red blood cells and serum in demented patients and in aging. J. Neurol. Sci., 1993, 115 : 18-25.
69. 2 receptors in dementia of the Alzheimer type : a quantitative autoradiographic study of frontal cortex and hippocampus. J. Neural. Transm., 1990, 2 : 129-137.
70. DEWAR D., CHALMERS D. T., GRAHAM D. I., MC CULLOCH. Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease : an autoradiographic study of the hippocampus. Brain Res., 1991, 553 : 58-64.
71. D'HOOGE R., NAGELS G., WESTLAND C. E., MUCKE L., DE DEYN P. P. Spatial learning deficit in mice expressing human 751-amino acid β-amyloid precursor protein. Neuroreport, in press.
72. EBINGER G., BRUYLAND M., MARTIN J. J., HERREGODTS P., CRAS P. et al. Distribution of biogenic amines and their catabolites in brains from patients with Alzheimer's disease. J. Neurol. Sci., 1987, 77 : 267-283.
73. EDVINSSON L., MINHON L., EKMAN R., GUSTAFSON L. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. Dementia, 1993, 4 : 167-171.
74. EMSON P. C., LINDVALL O. Neuroanatomical aspects of neurotransmitters affected in Alzheimer's disease. Br. Med. Bull., 1986, 42 : 57-62.
75. ESUMI E., ARAGA S., TAKAHASHI K. Serum interleukin-2 levels in patients with dementia of the Alzheimer type. Acta Neurol. Scand., 1991, 84 : 65-67.
76. FARLOW M., GRACON S. I., HERSHEY L. A., LEWIS K. W., SADOWSKY C. M. et al. A controlled trial of tacrine in Alzheimer's disease. JAMA, 1992, 268 : 2523-2529.
77. FLYNN D. D., FERRARI-DILEO G., MASH D. C., LEVEY A. I. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J. Neurochem., 1995, 64 : 1888-1891.
78. FOLSTEIN M. F., FOLSTEIN S. E., MCHUGH P. R. Minimental State : a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res., 1975, 12 : 189-198.
79. FRANCIS P. T., BOWEN D. M., NEARY D., PALO J., WIKSTROM J. et al. Somatostatin-like immunoreactivity in lumbar cerebrospinal fluid from neurohistologically examined demented patients. Neurobiol. Aging, 1984, 5 : 183-186.
80. FRANCIS P. T., PALMER A. M., SIMS N. R., BOWEN D. M., DAVISON A. M. et al. Neurochemical studies of early-onset Alzheimer's disease. N. Engl. J. Med., 1985, 313 : 7-11.
81. GABRIEL S. M., BIERER L. M., HAROUTUNIAN V., PUROHIT D. P., PERL D. P. et al. Widespread reductions in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex. Neurosci. Lett., 1993, 155 : 116-120.
82. GAMES D., ADAMS D., ALESSANDRINI R., BARBOUR R., BERTHELETTE P. et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature, 1995, 373 : 523-527.
83. GASPAR P., BERGER B., LESUR A., BORSOTTI J. P., FEBVRET A. Somatostatin 28 and neuropeptide Y innervation in the septal area and related cortical and subcortical structures of the human brain. Distribution, relationships and evidence for differential coexistence. Neuroscience, 1987, 22 : 49-73.
84. GASPAR P., DUYCKAERTS C., FEBVRET A., BENOIT R., BECK B. et al. Subpopulations of somatostatin-28 immunoreactive neurons display different vulnerability in senile dementia of the Alzheimer type. Brain Res., 1989, 490 : 1-13.
85. GASSEN M., GLINKA Y., YOUDIM M. B. H. Neuroprotection in progressive neurodegenerative disease of Alzheimer's disease and Parkinson's types : action of 1-deprenyl and rasagiline. In : Free Radicals in Brain Physiology and Disorders. PACKER L., HIRAMATSU M., YOSHIKAWA T. (eds.), San Diego, Academic Press, 1996, 293-312.
86. GLENNON R. A., TOTELER M., McKenney J. D. Structure-activity relationships and mechanisms of action of hallucinogenic agents based on drug discrimination and radioligand binding studies. Psychopharmacol. Bull., 1986, 22 : 953-958.
87. GOEDERT M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. TINS, 1993, 16 : 460-465.
88. GOLDGABER D., HARRIS H. W., HLA T., MACIAG T., DONNELLY R. J. et al. Interleukin-1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA, 1989, 86 : 7606-7610.
89. GOMEZ S., DAVOUS P., RONDOT P., FAIVRE-BAUMAN A., VALADE D. et al. Somatostatin-like immunoreactivity and acetylcholinesterase activities in cerebrospinal fluid of patients with Alzheimer disease and senile dementia of the Alzheimer type. Psychoneuroendocrinology, 1986a, 11 : 69-73.
90. GOMEZ S., PUYMIRAT J., VALADE P., DAVOUS P., RONDOT P., et al. Patients with Alzheimer's disease show an increased content of 15Kdalton somatostatin precursor and a lowered level of tetradecapeptide in their cerebrospinal fluid. Life Sci., 1986b, 39 : 623-627.
91. GOTTFRIES C. G., GOTTFRIES I., ROOS B. E. The investigation of homovanillic acid in the human brain and its correlation to senile dementia. Brit. J. Psychiat., 1969, 115 : 563-574.
92. GÖTZ M. E., KUNIG G., RIEDERER P., YOUDIM M. B. H. Oxidative stress : free radical production in neural degeneration. Pharmac Ther., 1994, 63 : 37-122.
93. GREENAMYRE J. T., PENNEY J. B., YOUNG A. B., D'AMATO C. L., HICKS S. P. et al. Alteration of L-glutamate binding in Alzheimer's and Huntington's diseases. Science, 1985, 227 : 1496-1499.
94. GREENAMYRE J. T., MARAGOS W. F. Neurotransmitter receptors in Alzheimer disease. Cerebrovasc. Brain Metab. Rev., 1993, 5 : 61-94.
95. GRIFFIN W. S. T., STANLEY L. C., LING Q, WHITE L., MACLEOD V. et al. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 1989, 86 : 7611-7615.
96. GRIFFIN W. S. T., SHENG J. G., ROBERTS G. W., MRAK R. E. Interleukin-1 expression in different plaque types in Alzheimer's disease : significance in plaque evolution. J. Neuropathol. Exp. Neurol., 1995, 54 : 276-281.
97. HALLIWELL B. Oxidants and the central nervous system : some fundamental questions. Is oxidant damage relevant to Parkinson's disease., Alzheimer's disease., traumatic injury or stroke ? Acta Neurol. Scand., 1989, 126S : 23-33.
98. HEINONEN E. H., SAVIJARVI M., KOTILA M., HAJBA A., SCHEININ M. Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. J. Neural. Transm. Park Dis. Dement. Sect., 1993, 5 : 193-202.
99. HENKE H., LANG W. Cholinergic enzymes in neocortex., hippocampus and basal forebrain of non-neurological and senile dementia of Alzheimer-type patients. Brain Res., 1983, 267 : 281-291.
100. HERREGODTS P., BRUYLAND M., DE KEYSER J., SOLHEID C., MICHOTTE Y. et al. Monoaminergic neurotransmitters in Alzheimer's disease. An HPLC study comparing familial and sporadic senile cases. J. Neurol. Sci., 1989a, 92 : 101-116.
101. HERREGODTS P., MICHOTTE Y., EBINGER G. Regional differences in the distribution of norepinephrine and epinephrine in human cerebral cortex : a neurochemical study using HPLC and electro-chemical detection. Neurosci. Lett., 1989b, 98 : 321-326.
102. HERREGODTS P., BRUYLAND M., MICHOTTE Y., EBINGER G. Alteration of the serotonergic neurotransmitter system in Alzheimer's disease : post-mortem comparison of presenile familial-type with senile sporadic cases. Alzheimer Dis. Assoc. Disord., 1989c, 3 : 25.
103. HERREGODTS P., EBINGER G., MICHOTTE Y. Distribution of monoamines in human brain : evidence for neurochemical heterogeneity in subcortical as well as cortical areas. Brain Res., 1991, 542 : 300-306.
104. HETIER E., AYALA J., DENEFLE P., BOUSSEAU A., ROUGET P. et al. Brain macrophages synthesize interleukin-1 and interleukin-1 mRNAs in vitro. J. Neurosci. Res., 1988, 21 : 391-397.
105. HIRAMATSU M., KOHNO M., MITSUTA K., MORI A. Increased superoxide dismutase activity in aged human cerebrospinal fluid and rat brain determined by electron spin resonance spectrometry using the spin trap method. J. Neurochem., 1992, 58 : 1160-1164.
106. HOLLANDER E., MOHS R. C., DAVIS K. L. Antemortem markers of Alzheimer's disease. Neurobiol. Aging, 1986, 7 : 367-386.
107. HUBERMAN M., SREDNI B., STERN L., KOTT E., SHALIT F. IL-2 and IL-6 secretion in dementia : correlation with type and severity of disease. J. Neurol. Sci., 1995, 130 : 161-164.
108. HUELL M., STRAUSS S., VOLK B., BERGER M., BAUER J. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol., 1995, 89 : 544-551.
109. IVERSEN L. L., ROSOR M. N., REYNOLDS G. P., HILLS R., ROTH M. et al. Loss of pigmented dopamine beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer type. Neurosci. Lett., 1983, 39 : 95-100.
110. JANSEN K. L. R., FAULL R. L. M., DRAGUNOW M., SYNEK B. L. Alzheimer's disease : changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors - an autoradiographic study. Neurosci., 1990, 39 : 613-627.
111. JEANDEL C., NICOLAS M. B., DUBOIS F., NABET-BELLEVILLE F., PENIN F. et al. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology, 1989, 35 : 275-282.
112. JENNER P. Oxidative damage in neurodegenerative disease. Lancet, 1994, 344 : 796-798.
113. KALARIA R. N. Characterization of (125I)HEAT binding to alpha 1-receptors in human brain : assessment in aging and Alzheimer's disease. Brain Res., 1989, 501 : 287-294.
114. 2-adrenergic receptors in cerebral microvessels in Alzheimer's disease. Neurosci. Lett., 1989, 106 : 233-238.
115. KALARIA R. N., ANDORN A. C., TABATON M., WHITEHOUSE P. J., HARIK S. I. et al. Adrenergic receptors in aging and Alzheimer's disease : increased beta 2-receptors in prefrontal cortex and hippocampus. J. Neurochem., 1989, 53 : 1772-1781.
116. 3H)p-aminoclonidine binding in prefrontal cortex. Neurobiol. Aging, 1991, 12 : 131-136.
117. KAYE J. A., MAY C., DALY E., ATACK J. R., Sweeney D. J. et al. Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features. Neurology, 1988a, 38 : 554-557.
118. KAYE J. A., MAY C., ATACK J. R., DALY E., SWEENEY D. L. et al. Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. Ann. Neurol., 1988b, 24 : 648-650.
119. KNAPP M. J., KNOPMAN D. S., SOLOMON P. R., PENDLEBURRY W. W., DAVIS C. S. et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA, 1994, 271 : 985-991.
120. KNOPMAN D., SCHNEIDER L., DAVIS K., TALWALKER S., SMITH F. et al. Long-term tacrine (Cognex) treatment : effects on nursing home placement and mortality. Neurology, 1996, 47 : 166-177.
121. KOWALL N. W., BEAL M. F. Cortical somatostatin., neuropeptide Y and NADPH diaphorase neurons : normal anatomy and alterations in Alzheimer's disease. Ann. Neurol., 1988, 23 : 105-114.
122. KRANTIC S., ROBITAILLE Y., QUIRION R. Deficits in the somatostatin SSI receptor subtype in frontal and temporal cortices in Alzheimer's disease. Brain Res., 1992, 573 : 299-304.
123. KUROBE N., INAGAKI T., KATO K. Sensitive enzyme immunoassay for human Mn superoxide dismutase. Clin. Chim. Acta, 1990, 192 : 171-180.
124. LEYSEN J. E., VAN GOMPEL P., VERWIMP M., NIEMEYEERS C. J. Role and localisation of serotonin-2 receptor binding sites : effects of neuronal lesions. In : CNS receptors from molecular pharmacology to behavior. MANDEL P., DEFEUDIS F. V., (eds.) New York, Raven Press, 1983, 373-383.
125. MANDYBUR T. I., CHUIRAZZI B. A. Astrocytes and the plaques of Alzheimer's disease. Neurology, 1990, 40 : 635-639.
126. MANN D. M. A., LINCOLN J., YATES P. O., STAMP J. F., TOPEZ S. Changes in the monoamine containing neurons of the human CNS in senile dementia. Brit. J. Psychiat., 1980, 136 : 533-541.
127. MANN D. M. A., YATES P. I., MARCYNIUK B. A comparison of changes in the nucleus basalis and locus coeruleus in Alzheimer's disease. J. Neurol. Neurosurg. Psychiat., 1984, 47 : 201-203.
128. MANN J. J., STANLEY M., NEOPHYTIDES A., DE LEON M. J., FERRIS S. H. et al. Central amine metabolism in Alzheimer's disease : in vivo relationship to cognitive deficit. Neurobiol. Aging, 1981, 2 : 57-60.
129. MARKLUND S. L., ADOLFSSON R., GOTFRIESS C. G., WINBLAD B. Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J. Neurol. Sci., 1985, 67 : 319-325.
130. MARSHAK D. R., PESCE S. A., STANLEY L. C., GRIFFIN W. S. Increased S100β neurotrophic activity in Alzheimer's disease temporal lobe. Neurobiol. Aging, 1992, 13 : 1-7.
131. MARTIGNONI E., BLANDINI F., PETRAGLIA F., PACCHETTI C., BONO G. et al. Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease., multiple system atrophy and dementia of the Alzheimer type. J. Neural. Transm. Park Dis. Dement. Sect., 1992, 4 : 191-205.
132. MARTIN E. M., WILSON R. S., PENN R. S., Fox J. H., CLASEN R. A. et al. Cortical biopsy results in Alzheimer's disease : correlation with cognitive deficits. Neurology, 1987, 37 : 1201-1204.
133. MARTINEZ M., FRANK A., DIEZ-TEJEDOR E., HERMANZ A. Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia. J. Neural. Transm., 1993, 6 : 1-9.
134. MASH D. C., FLYNN D. D., POTTER L. T. Loss of μ2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science, 1985, 228 : 1115-1117.
135. MCGEER E. G. Aging and neurotransmitter metabolism in the human brain. In : Alzheimer's Disease : Senile Dementia and Related Disorders (Aging). KATZMAN R., TERRY R. D., BICK K. L. (Eds.) New York, Raven Press, 1978, Vol. 7 : 427-440.
136. 2-adrenoreceptors in post-mortem brains of patients with Alzheimer's disease. J. Neurochem., 1992, 58 : 1896-1904.
137. MELTZER H. Y. Role of serotonin in depression. Ann. N. Y. Acad. Sci., 1990, 600 : 486-499.
138. MINTHON L., EDVINSSON L., EKMAN R., GUSTAFSON L. Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration. J. Neural. Transm. Suppl., 1990, 30 : 57-67.
139. MOLCHAN S. E., LAWLOR B. A., HILL J. L., MARTINEZ R. A., DAVIS C. L. et al. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol. Psychiatry, 1991, 29 : 1110-1118.
140. MORAN P. M., HIGGINS L. S., CORDELL B., MOSER P. C. Age-related learning deficits in transgenic mice expressing the 75I-amino acid isoform of human beta-amyloid precursor protein. Proc. Natl. Acad. Sci. USA, 1995, 92 : 5341-5345.
141. MRAK R. E., SHENG J. G., GRIFFIN S. T. Glial Cytokines in Alzheimer's Disease : Review and Pathogenic Implications. Hum. Pathol., 1995, 26 : 816-823.
142. MUCKE L., MASLIAH E., JOHNSON W. B., RUPPE M. D., ALFORD M. et al. Synaptotrophic effects of human amyloid beta protein precursor in the cortex of transgenic mice. Brain Res., 1994, 666 : 151-167.
143. MULLER W. E., SCHEUER K., STOLL S. Glutamatergic treatment strategies for age-related memory disorders. Life Sci., 1994, 55 (25/26) : 2147-2153.
144. NAKASHIMA S., IKUTA F. Catecholamine neurons with Alzheimer's neurofibrillary changes and alteration of tyrosine hydroxylase. Acta Neuropathol. (Berl.), 1985, 66 : 37-41.
145. NAVARATNAM D. S., PRIDDLE J. D., MCDONALD B., ESIRI M. M., ROBINSON J. R. et al. Anomalous molecular form of acetylcholinesterase in cerebrospinal fluid in histologically diagnosed Alzheimer's disease. Lancet, 1991, 337 : 447-450.
146. NIEUWENHUYS R. Chemoarchitecture of the Brain. Berlin, Springer-Verlag, 1985.
147. NIEUWENHUYS R., VOOGD J., VAN HUIJZEN C. The Human Central Nervous System : a Synopsis and Atlas. Berlin, Springer-Verlag, 3rd edition, 1988.
148. OERTEL W. H., GRAYBIEL A. M., MUGNAINI E., ELDE R. P., SCHMECHEL D. E. et al. Coexistence of glutamic acid decarboxylase- and somatostatin-like immunoreactivity in neurons of the feline nucleus reticularis thalami. J. Neurosci., 1983, 3 : 1322-1332.
149. OHARA K., KONDO N., XIE D., TANABE K., YAMAMOTO T. et al. Normal sequences of muscarinic acetylcholine receptors (μ1 and μ2) in patients with Alzheimer's disease and vascular dementia. Neurosci. Lett., 1994, 178 : 23-26.
150. OLANOW C. W. A radical hypothesis for neurodegeneration. Trends Neurosci., 1993, 16 : 439-444.
151. OLNEY J. W. Excitatory transmitter neurotoxicity. Neurobiol. Aging, 1994, 15 : 259-260.
152. 1Adrenergic receptor binding sites in post-mortal human cerebral microvessel preparations : preservation in multi-infarct dementia and dementia of the Alzheimer type. J. Neural. Transm., 1989, 1 : 303-310.
153. O'NEILL C., COWBURN R. F., WIEHAGER B., ALAFUZOFF I., WINBLAD B. et al. Preservation of 5-hydroxytryptamine1A receptor-G protein interactions in the cerebral cortex of patients with Alzheimer's disease. Neurosci. Lett., 1991, 133 : 15-19.
154. ORAM J. J., EDWARDSON J., MILLARD P. H. Investigation of cerebrospinal fluid neuropeptides in idiopathic senile dementia. Gerontology, 1981, 27 : 216-223.
155. PALMER A. M., SIMS N. R., BOWEN D. M., NEARY D., PALO J. et al. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J. Neurol. Neurosurg. Psychiatry, 1984, 47 : 481-484.
156. PALMER A. M., WILCOCK G. K., ESIRI M. M., FRANCIS P. T., BOWEN D. M. Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Res., 1987, 401 : 231-238.
157. PALMER A. M., STRATMAN G. C., PROCTER A. W., BOWEN D. M. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann. Neurol., 1988, 23 : 616-620.
158. PAPPOLLA M. A., OMAR R. A., KIM K. S., ROBAKIS N. K. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am. J. Pathol., 1992, 140 : 621-628.
159. PATEL Y. C., GREENWOOD M. T., WARSZYNSKA A., PANETTA R., SRIKANT C. B. All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem. Biophys. Res. Commun., 1994, 198 : 605-612.
160. PERRIN R., BRIANÇON S., JEANDEL C., ARTUR Y., MINN A. et al. Blood activity of Cu/Zn superoxide dismutase., glutathione peroxidase and catalase in Alzheimer's disease : a case-control study. Gerontology, 1990, 36 : 306-313.
161. PERRY E. K., TOMLINSON B. E., BLESSED G., BERGMANN K. and GIBSON P. H. et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J., 1978, 2 : 1457-1459.
162. PERRY E. K., PERRY R. H., CANDY J. M., FAIRBAIRN A. F., BLESSED G. et al. Cortical serotonin-S2 receptor binding abnormalities in patients with Alzheimer's disease. Neurosci. Lett., 1984, 51 : 353-357.
163. PERRY E. K., GIBSON P. H., BLESSED G., PERRY R. H., TOMLINSON B. E. Neurotransmitter enzyme abnormalities in senile dementia. J. Neurol. Sci., 1987, 34 : 247-265.
164. PERRY R. H., CANDY J. M., PERRY E. K., IRVING D., BLESSED G. et al. Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease. Neurosci. Lett., 1982, 33 : 311-315.
165. 3H)MK-801binding in Alzheimer's disease. J. Neurochem., 1989, 53 : 698-704.
166. QUIRION R., RICHARD J., DAM T. V. Evidence for the existence of serotonin type-2 receptors on cholinergic terminals in rat cortex. Brain Res., 1985, 333 : 345-349.
167. QUON D., WANG Y., CATALANO R., SCARDINA J. M., MURAKAMI K. et al. Formation of beta amyloid protein deposits in brain of transgenic mice. Nature, 1991, 352 : 239-241.
168. RASKIND M. A., PESKIND E. R., HALTER J. B., JIMERSON D. C. Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arch. Gen. Psychiatry, 1984, 41 : 343-346.
169. RASKIND M. A., PESKIND E. R., LAMPE T. H., RISSE S. C., TABORSKY G. J. et al. Cerebrospinal fluid vasopressin, oxytocin, somatostatin and beta-endorphin in Alzheimer's disease. Arch. Gen. Psychiatry, 1986, 43 : 382-388.
170. REICHLIN S. Somatostatin (first of two parts). N. Engl. J. Med., 1983, 309 : 1495-1501.
171. REICHLIN S. Somatostatin (second of two parts). N. Engl. J. Med., 1983, 309 : 1556-1563.
172. REINIKAINEN K. J., RIEKKINEN P. J., JOLKKONEN J., KOSMA V. M., SOININEN H. Decreased somatostatin-like immunoreactivity in cerebral cortex and cerebrospinal fluid in Alzheimer's disease. Brain Res., 1987, 402 : 103-108.
173. REUBI J. C., KVOLS L., KRENNING E., LAMBERTS S. W. J. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism, 1990, 39 : 78-81.
174. 2 receptors in senile dementia of the Alzheimer type. Neurosci. Lett., 1984, 44 : 47-51.
175. RIGHI M., MORI L., DELIBERO G., SIRONI M., BIONDI A. et al. Monokine production by microglial cell clones. Eur. J. Immunol., 1989, 19 : 1443-1448.
176. RINNE J. O., RINNE J. K., LAASKO K., PALJÄRVI L., RINNE U. K. Reduction in muscarinic receptor binding in limbic areas of Alzheimer brain. J. Neurol. Neurosurg. Psychiatry, 1984, 47 : 651-653.
177. RINNE J. O., SÄKO E., PALJÄRVI L., MÖLSA L., RINNE U. K. Brain dopamine D-1 receptors in senile dementia. J. Neurol. Sci., 1986a, 73 : 219-230.
178. RINNE J. O., SÄKO E., PALJÄRVI L., MÖLSA L., RINNE U. K. Brain dopamine D-2 receptors in senile dementia. J. Neural. Transm., 1986b, 65 : 51-62.
179. ROBERTS G. W., LOFTHOUSE R., ALLSOP D., LANDON M., KIDD M. et al. CNS amyloid proteins in neurodegenerative diseases. Neurology, 1988, 39 : 1534-1540.
180. ROGERS J., COOPER N. R., WEBSTER S., SCHULTZ J., MCGEER P. L. et al. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1992, 89 : 10016-10020.
181. ROSSOR M. N., EMSON P. C., MOUNTJOY C. Q., ROTH M., IVERSON L. L. Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci. Lett., 1980, 20 : 373-377.
182. SCHMECHEL D. E., VICKREY B. G., FITSPATRICK R. P., ELDE R. P. GABAergic neurons of mammalian cerebral cortex : widespread subclass defined by somatostatin content. Neurosci. Lett., 1984, 47 : 227-232.
183. SERBY M., RICHARDSON S. B., TWENTE S., SIEKIERSKI J., CORWIN J. et al. CSF somatostatin in Alzheimer's disease. Neurobiol. Aging, 1984, 5 : 187-189.
184. SHENG J. G., MRAK R. E., GRIFFIN W. S. T. S100β protein expression in Alzheimer's disease : potential role in the pathogenesis of neuritic plaques. J. Neurosci. Res., 1994, 39 : 398-404.
185. SHENG J. G., MRAK R. E., GRIFFIN W. S. T. Interleukin-1α expression in brain regions in Alzheimer's disease : correlation with neuritic plaque distribution. J. Neuropathol. Exp. Neurol., 1995, 54 : 435.
186. SHIMOHAMA S., TANIGUCHI T., FUJIWARA M., KAMEYAMA M. Biochemical characterization of α-adrenergic receptors in human brain and changes in Alzheimer-type dementia. J. Neurochem., 1986, 47 : 1294-1301.
187. SHIMOHAMA S., TANIGUCHI T., FUJIWARA M., KAMEYAMA M. Changes in β-adrenergic receptor subtypes in Alzheimer-type dementia. J. Neurochem., 1987, 48: 1215-1221.
188. SIEGEL G. J., AGRANOFF B. W., ALBERS R. W., MOLINOFF P. B., eds. Basic Neurochemistry, 5th edition. New York, Raven, 1994.
189. SIMS N. R., BOWEN D. M., SMITH C. C., FLACK R. H., DAVISON A. N. et al. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet, 1980, 1 (8164) : 333-336.
190. SIMS N. R., BOWEN D. M., ALLEN S. J., SMITH C. C. T., NEARY D. et al. Presynaptic cholinergic dysfunction in patients with dementia. J. Neurochem., 1983, 40 : 503-509.
191. SORENSEN K. V., CHRISTENSEN S. E., HANSEN A. P., INGERSLEV J., PEDERSEN E. et al. The origin of cerebrospinal fluid somatostatin : hypothalamic or disperse central nervous system secretion. Neuroendocrinology, 1981, 32 : 335-338.
192. SPARKS D. L., HUNSAKER J. C., SLEVIN J. T., DEKOSKY S. T., KRYSCIO R. J. et al. Monoaminergic and cholinergic synaptic markers in the nucleus basalis of Meynert : normal age-related changes and the effect of heart disease and Alzheimer's disease. Ann. Neurol., 1992, 31 : 611-620.
193. SULKAVA R., NORDBERG U.-R., ERKINJUNTTI T., WESTERMARCK T. Erythrocyte glutathione peroxidase and superoxide dismutase in Alzheimer's disease and other dementias. Acta Neurol. Scand., 1986, 73 : 487-489.
194. TAMMINGA C. A., FOSTER N. L., FEDIO P., BIRD E. D., CHASE T. N. Alzheimer's disease : low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology, 1987, 37 : 161-165.
195. TOHGI T., ABE T., TAKAHASHI S., KIMURA M., TAKAHASHI J et al. Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci. Lett., 1992, 141 : 9-12.
196. TOHGI T., TAKAHASHI S., ABE T. The effect of age on concentration of monoamines., amino acids and their related substances in the cerebrospinal fluid. J. Neural. Transm., 1993, 5 : 215-226.
197. TOHGI H., ABE T., HASHIGUCHI K., SAHEKI M., TAKAHASHI S. Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci. Lett., 1994, 177 : 139-142.
198. TOMLINSON B. E., IRVING D., BLESSED G. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J. Neurol. Sci., 1981, 49 : 419-428.
199. UNGER J. W., MCNEILL T. H., LAPHAM L. L., HAMILL R. W. Neuropeptides and neuropathology in the amygdala in Alzheimer's disease : relationship between somatostatin, neuropeptide Y and subregional distribution of neuritic plaques. Brain Res., 1988, 452 : 293-302.
200. URAKAMI K., ADACHI Y., AWAKI E., TAKAHASHI K. Characterization of the course of senile dementia of the Alzheimer type using cerebrospinal fluid levels of acetylcholinesterase and somatostatin. Acta Neurol. Scand., 1989, 80 : 232-237.
201. VAN DONGEN P. A. M. The human locus coeruleus in neurology and psychiatry. Prog. Neurobiol., 1981, 17 : 97-139.
202. VAN DUIJN C. M., HOFMAN A., NAGELKERKEN L. Serum levels of IL-6 are not elevated in patients with Alzheimer's disease. Neurosci. Lett., 1990, 108 : 350-354.
203. VAN ELDIK L. J., GRIFFIN W. S. T. S100β expression in Alzheimer's disease : relation to neuropathology in brain regions. Biochim. Biophvs. Acta, 1994, 1223 : 398-403.
204. VIJAYASHANKAR N., BRODY H. A quantitative study of the pigmented neurons in the nuclei locus coeruleus and subcoeruleus in man as related to aging. J. Comp. Neurol., 1979, 38 : 490-497.
205. VOGT B. A., CRINO P. B., VOLICER L. Laminar alterations in gammα-aminobutyric acid A, muscarinic and beta adrenoreceptors and neuron degeneration in cingulate cortex in Alzheimer's disease. J. Neurochem., 1991, 57 : 282-290.
206. VOLICER L., DIRENFELD L. K., LANGLAIS P. J., FREEDMAN M., BIRD E. D. et al. Catecholamine metabolites and cyclic nucleotides in cerebrospinal fluid in dementia of Alzheimer type. J. Gerontol, 1985, 40 (6): 708-713.
207. VOLICER L., CRINO P. B. Involvement of free radicals in dementia of the Alzheimer type : a hypothesis. Neurobiology of Aging, 1990, 11 : 567-571.
208. WALKER L. C., KITT C. A., CORK L. C., STRUBLE R. G., DELLOVADE T. L. et al. Multiple transmitter systems contribute neuntes to individual senile plaques. J. Neuropathol. Exp. Neurol., 1988, 47 : 138-144.
209. WESTERINK B. H. C., DE VRIES J. B. On the origin of dopamine and its metabolite in predominantly noradrenergic innervated brain areas. Brain Res., 1985, 330 : 146-166.
210. WHITEHOUSE P. J., PRICE D. L., STRUBLE R. G., CLARK A. W., COYLE J. T. et al. Alzheimer's disease and senile dementia : loss of neurons in the basal forebrain. Science. 1982, 215 : 1237-1239
211. WHITFORD C., CANDY J., EDWARDSON J., PERRY R. Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases. J. Neurol. Sci., 1988, 86 : 13-18.
212. WILCOCK G. K., ESIRI M. M., BOWEN D. M., SMITH C. C. T. Alzheimer's disease : correlation of cortical choline acetyltransferase activity with severity of dementia and histological abnormalities. J. Neurol. Sci., 1982, 57 : 407-417.
213. WOOD J. A., WOOD P. L., RYAN R., GRAFF-RADFORD N. R., PILAPIL C. et al. Cytokine indices in Alzheimer's temporal cortex : no changes in mature IL-1 beta or IL-1 RNA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res., 1993, 629 : 245-252.
214. WOOD P. L., ETIENNE P., LAL S., GAUTHIER S., CAJAL S. et al. Reduced lumbar CSF somatostatin levels in Alzheimer's disease. Life Sci., 1982, 31 : 2073-2079.
215. YAMADA K., KONO K., UMEGAKI H., YAMADA K., IGUCHI A. et al. Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia. Neurosci. Lett., 1995, 186 : 219-221.
216. YATES C. M., ALLISON Y., SIMPSON J., MALONEY A. F., GORDON A. Dopamine in Alzheimer's disease and senile dementia. Lancet, 1979, I : 851-852.
217. YATES C. M., SIMPSON J., GORDON A., MALONEY A. F. J., ALLISON Y. et al. Catecholamines and cholinergic enzymes in presenile and senile Alzheimer-type dementia and Down's syndrome. Brain Res., 1983, 280 : 119-126.
218. YOUNG A. B., PENNEY J. B. Neurotransmitter receptors in Alzheimer disease. In : Alzheimer Disease. TERRY R. D., KATZMAN R., BICK K. L. (eds.), New York, Raven, 1994, 293-303.
219. ZAMAN Z., ROCHE S., FIELDEN P., FROST P. G., NIRIELLA D. C. et al. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age and Aging, 1992, 21 : 91-94.
220. ZEMLAN F. P., THIENHAUS O. J., BOSMANN H. B. Superoxide dismutase activity in Alzheimer's disease. Possible mechanism for paired helical filament formation. Brain Res., 1989, 476: 160-162.
221. ZIMMER R., TEELKEN A. W., TRIELING W. R., WEBER W., WEIHMAYR T. et al. γ-Aminobutyric acid and homovanillic acid concentration in the CSF of patients with senile dementia of Alzheimer's type. Arch. Neurol., 1984, 41 : 602-604.
222. ZUBENKO G. S., MOOSSY J. Major depression in primary dementia. Clinical and neuropathologic correlates. Arch. Neurol., 1988, 45 : 1182-1186.
223. ZUBENKO G. S., SAUER P. SOD-1 activity and platelet membrane fluidity in Alzheimer's disease. Biol. Psych., 1989, 25 : 671-678.
224. ZUBENKO G. S., MOOSSY J., KOPP U. Neurochemical correlates of major depression in primary dementia. Arch. Neurol., 1990, 47 : 209-214.
225. ZUBENKO G. S., MOOSSY J., MARTINEZ A. J., RAO G., CLAASSEN D. et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch. Neurol., 1991, 48 : 619-624.
226. ZWEIG R. M., ROSS C. A., HEDREEN J. C., STEELE C., CARDILLO J. E. et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann. Neurol., 1988, 24 : 233-242.